PreveCeutical Welcomes Stephen Glover as Corporate Advisor
PreveCeutical Medical (OTCQB: PRVCF) has appointed Stephen Glover as Corporate Advisor, effective May 24, 2025. The health sciences company, which focuses on developing innovative preventive and curative therapies using organic and nature-identical products, expects to benefit from Glover's extensive experience in biopharma, corporate strategy, commercialization, and financial management. CEO Stephen Van Deventer emphasized Glover's proven leadership and track record in building and transforming organizations as key assets for advancing PreveCeutical's therapeutic development mission.
PreveCeutical Medical (OTCQB: PRVCF) ha nominato Stephen Glover come Consulente Aziendale, a partire dal 24 maggio 2025. L'azienda nel settore delle scienze della salute, che si concentra sullo sviluppo di terapie preventive e curative innovative utilizzando prodotti organici e identici a quelli naturali, prevede di trarre vantaggio dall'ampia esperienza di Glover nel campo della biofarmaceutica, della strategia aziendale, della commercializzazione e della gestione finanziaria. Il CEO Stephen Van Deventer ha sottolineato come la leadership comprovata di Glover e il suo storico di successi nella costruzione e trasformazione delle organizzazioni rappresentino risorse fondamentali per far progredire la missione di sviluppo terapeutico di PreveCeutical.
PreveCeutical Medical (OTCQB: PRVCF) ha designado a Stephen Glover como Asesor Corporativo, con efecto desde el 24 de mayo de 2025. La empresa de ciencias de la salud, que se enfoca en desarrollar terapias preventivas y curativas innovadoras utilizando productos orgánicos e idénticos a los naturales, espera beneficiarse de la amplia experiencia de Glover en biofarmacia, estrategia corporativa, comercialización y gestión financiera. El CEO Stephen Van Deventer destacó el liderazgo comprobado de Glover y su historial en la construcción y transformación de organizaciones como activos clave para avanzar en la misión de desarrollo terapéutico de PreveCeutical.
PreveCeutical Medical (OTCQB: PRVCF)는 2025년 5월 24일부로 Stephen Glover를 기업 고문으로 임명했습니다. 유기농 및 자연 동일 제품을 사용한 혁신적인 예방 및 치료 요법 개발에 중점을 둔 이 건강 과학 회사는 Glover의 바이오제약, 기업 전략, 상업화 및 재무 관리 분야에서의 풍부한 경험을 활용할 것으로 기대하고 있습니다. CEO Stephen Van Deventer는 조직을 구축하고 변화시킨 Glover의 입증된 리더십과 성과가 PreveCeutical의 치료 개발 미션을 진전시키는 데 핵심 자산임을 강조했습니다.
PreveCeutical Medical (OTCQB : PRVCF) a nommé Stephen Glover en tant que Conseiller d'Entreprise, à compter du 24 mai 2025. Cette société des sciences de la santé, qui se concentre sur le développement de thérapies préventives et curatives innovantes utilisant des produits organiques et identiques à ceux de la nature, prévoit de bénéficier de la vaste expérience de Glover dans le domaine de la biopharmacie, de la stratégie d'entreprise, de la commercialisation et de la gestion financière. Le PDG Stephen Van Deventer a souligné que le leadership avéré de Glover et son parcours dans la construction et la transformation d'organisations constituent des atouts clés pour faire avancer la mission de développement thérapeutique de PreveCeutical.
PreveCeutical Medical (OTCQB: PRVCF) hat Stephen Glover mit Wirkung zum 24. Mai 2025 als Unternehmensberater ernannt. Das Gesundheitswissenschaftsunternehmen, das sich auf die Entwicklung innovativer präventiver und kurativer Therapien mit organischen und naturidentischen Produkten spezialisiert hat, erwartet, von Glovers umfangreicher Erfahrung in Biopharma, Unternehmensstrategie, Kommerzialisierung und Finanzmanagement zu profitieren. CEO Stephen Van Deventer betonte Glovers nachgewiesene Führungsqualitäten und seine Erfolgsbilanz beim Aufbau und der Transformation von Organisationen als wichtige Vermögenswerte zur Förderung der therapeutischen Entwicklungsmission von PreveCeutical.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that Steve Glover has been appointed as Corporate Advisor effective on 24 May, 2025.
Stephen Van Deventer, CEO of PreveCeutical, commented:
"We are honoured to welcome Stephen Glover as our Corporate Advisor. Stephen's proven leadership in biopharma, combined with his expertise in corporate strategy, commercialization, and financial management, makes him an invaluable addition to our team. His track record of building and transforming organizations aligns seamlessly with PreveCeutical's mission to advance groundbreaking therapies."
About Stephen Glover:
Stephen Glover is an accomplished executive with over three decades of leadership experience in the biopharma industry. Currently, he serves as Chairman and CEO of ZyVersa Therapeutics, a clinical-stage specialty biopharmaceutical company focused on innovative treatments for inflammatory and kidney diseases. Stephen has successfully led multiple organizations, securing over
Previously, Stephen was Chairman of Ambrx, overseeing its
In addition to his extensive executive experience, Stephen serves on the board of publicly traded companies, including as Chairman of PDS Biotechnology, a NASDAQ company and the University of Miami Coulter Foundation, bringing insights into audit, compensation, and governance practices.
Stephen Glover remarked on his appointment:
"I am excited to join PreveCeutical and work with the leadership team to expand the application and growth of their exciting Sol-Gel program in multiple therapeutic categories. The growth of the nasal delivery market over the next few years represents a great opportunity to develop new products for significant unmet medical needs and provide patients with a better option for treatments in many disease areas."
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On Behalf of the Board of Directors,
PreveCeutical Medical Inc.
"Stephen Van Deventer"
Chairman & Chief Executive Officer
For further information, please contact:
Stephen Van Deventer
(604) 306-9669
info@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future, including, without limitation, the continued research interests of PreveCeutical, PreveCeutical's anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "will", "pro forma", "plans", "expects", "may", "should", "budget", "schedules", "estimates", "forecasts", "intends", "anticipates", "believes", "potential", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical's research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical's filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), its Regulation Services Provider (as that term is defined in policies of the CSE), nor any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only, and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253362
FAQ
Who is Stephen Glover and what is his new role at PreveCeutical (PRVCF)?
What does PreveCeutical Medical (PRVCF) specialize in?
When did Stephen Glover join PreveCeutical (PRVCF) as Corporate Advisor?
Who is the CEO of PreveCeutical Medical (PRVCF)?
